Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.46 – $5.90
5% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $113.0M | $126.2M | $110.3M | $348.1M | $361.3M | $153.7M | $169.6M | $174.7M |
| Cost of revenue | $43.4M | $50.0M | $54.3M | $187.9M | $324.4M | $100.9M | $98.5M | $107.1M |
| Gross profit | $69.6M | $76.2M | $56.0M | $160.2M | $36.9M | $52.8M | $71.0M | $67.5M |
| Gross margin | 61.6% | 60.4% | 50.8% | 46.0% | 10.2% | 34.4% | 41.9% | 38.7% |
| R&D | $12.2M | $37.9M | $84.5M | $173.3M | $104.9M | $59.9M | $74.1M | $85.3M |
| Operating income | $6.3M | −$811.0K | −$55.1M | −$61.4M | −$113.4M | −$82.1M | $13.3M | −$81.6M |
| EBITDA | $14.0M | $10.3M | −$44.8M | −$38.7M | −$104.7M | −$57.7M | $32.1M | −$50.5M |
| Net income | $3.3M | −$1.7M | −$64.4M | −$73.4M | −$143.3M | −$101.4M | −$12.2M | −$115.2M |
| Net margin | 2.9% | -1.4% | -58.4% | -21.1% | -39.7% | -66.0% | -7.2% | -66.0% |
| EPS (diluted) | 0.04 | -0.02 | -0.71 | -0.75 | -1.24 | -0.73 | -0.09 | -0.68 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $154M | $-0.38 | $-0.51–$-0.31 | 1 |
| 2027 | $298M | $0.33 | $0.27–$0.44 | 1 |
| 2028 | $251M | $0.20 | $0.16–$0.27 | 1 |
| 2029 | $309M | $0.40 | $0.33–$0.54 | 1 |
Forward consensus · source: Financial Modeling Prep
VALNEVA SE ORD
No one on the platform currently holds INRLF.
No tracked institution reports a position in INRLF as of their last filing.
No one on the platform has traded INRLF yet.
| $15M |
| — |
| IDRSFIdorsia Ltd | $7.40 | +0.00% | $1.9B | — |
| MDCLFMedinCell S.A. | $34.39 | +0.00% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.9× sales vs its 4.2× historical median P/S.
Fair value ≈ $5.93 · price $2.62 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.